Overview
Interacts with the VEGFR2 and FAK pathways in intestinal epithelium, promoting cell migration and proliferation.
Proposed mechanism
Oral BPC-157 is formulated to survive gastric acid, then binds to growth factor receptors in the GI tract, stimulating angiogenesis and tissue repair.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
BPC-157 stable gastric pentadecapeptide
· DOI:10.3390/ph13090268 · 2020
- [2]
Oral BPC-157 GI healing
· DOI:10.1016/j.peptides.2014.03.002 · 2014
- [3]
BPC-157 stable gastric pentadecapeptide (2020)
· · 0
- [4]
Oral BPC-157 GI healing (2014)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.